SyB L-0501
SyB L-0501 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical Trials (6)
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6